We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Brainjuicer | LSE:BJU | London | Ordinary Share | GB00B1GVQH21 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 787.50 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 787.50 | GBX |
Brainjuicer (BJU) Share Charts1 Year Brainjuicer Chart |
|
1 Month Brainjuicer Chart |
Intraday Brainjuicer Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 03/4/2017 | 07:34 | Brainjuicer - Fresher Insights, Better Marketing | 275 |
| 07/6/2011 | 11:17 | Brainjuicer | 185 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 03/3/2017 21:15 by saturn5 Some of these have lovely chartsPVG BJU FARN WAND BOO We've struck gold here All those shares are 100% BUYS |
Posted at 28/2/2017 09:45 by longshanks No worries.ODX is definitely the one I favour for short-term appreciation. A baillie Gifford fund manager has built up a personal stake of 11% - and I think it is good for a 50-100% share price rise over the next 6-12 months.The share at the bottom of my list: SPHR is a real basket case though and I certainly wouldn't buy just yet. Results announced today were awful. |
Posted at 27/2/2017 19:13 by saturn5 Lets hope it all goes wellAs a side issue I bought an Android Tablet on Ebay (£50) and I use it every day I have an App on it with four different portfolios that show Share prices and charts daily and long term line and candle ones too But for share chat ADVFN is best |
Posted at 27/2/2017 17:13 by longshanks With regard to the rebranding, I would recommend watching the video in the link I posted over the weekend.I think the company know what they are doing. Having grown from a £15m outfit to a near £100m outfit, they want to reenergise the business for the next phase of growth that could well take them into the FTSE 250. They have taken soundings from their largest investors who seem wholly supportive and whilst the process is not without its risks - their core client base is small and easy to manage so should be easy to align. Overall I am excited about this next phase and the rebranding. If they can generate 30% CAGR each year for the next four years then this will become a very different company. I also love the fact that they are doing the rebrand on April fool's day! ---- Regarding your purchase price: I would forget about it. You certainly haven't bought the shares cheap, but they are fair value. Better to have bought at £7.25 than >£8 as some have. The company is throwing off cash, and without any acquisition targets in sight will be returning a lot of that cash to shareholders. If they achieve their growth targets organically, that rate of cash return is only going to accelerate. You should look at holding shares over the long term and something like BJU/SYS1 with low liquidity and a trading spread of approx. 30p really discourages any short term trading activity. |
Posted at 27/2/2017 14:55 by longshanks Investing in shares can be a painful process; there are no magic formulae for success unfortunately.Avoid buying when the market is too hot (e.g. after news releases) and wait when share prices are dropping because they will probably drop further - are my two cardinal rules.I research my stocks carefully and tend to try and buy when no-one else is buying.No advice intended, but here is:Longshanks' bakers dozenIMM - immupharma ODX - Omega diagnosticsLTG - leaning technology groupSCE - surface TransformsVLE - volvereBJU - brainjuicer FARN - faron pharmaceuticalsNFC - next fifteen communicationsSOM - somero enterprisesHUR - hurricane energyRWS - RWS holdingsPTSG - premier technical servicesSPHR - sphere medical This is in my investing order of preference. IMM has astonishing potential. It is less than a year away from completing a phase 3 trial on a drug with blockbuster potential (>$1bn sales pa). Market is gradually waking up to that potential and you can still buy in cheap. It looks like a binary option on success of this drug, but the phase 2 data was so good it has been given the FDA special protocol assessment. The chances of success are far higher than for your typical drug trial.All the others are worth researching. I don't have stakes in them all - but they are all very much on my active watch list. |
Posted at 24/2/2017 13:01 by longshanks I guess the point is that if they achieve profits of 185% above those of today's, then the share price will be much, much higher in 4 years time and we should be happy to have this level of dilution. A vesting threshold of 10% pa (46% over 4 years) seems reasonable.This is a "people business" and they need to retain the brightest and best. |
Posted at 24/2/2017 11:30 by dab26 --------------------Operation The new LTIP will run for a four-year period, commencing on 1 April 2017 with vesting dependent on the achievement of stretching performance conditions. We anticipate the 3 Executive Directors excluding the Chief Executive Officer (see below) and 4 Senior Executives will participate with opportunity levels dependent on seniority. Awards will be made in the form of nil cost options or conditional shares (where appropriate for local tax/legal reasons). Award levels The maximum individual opportunity that will be granted under the LTIP is as follows: • Executive Directors: 1.50% of the issued share capital1 • Senior Executives: 1.00% of the issued share capital The total number of shares that can therefore be granted under the LTIP is equal to 8.5% of the issued share capital. Performance Conditions Awards will be subject to stretching Gross Profit growth targets. This will be measured based on the compound annual growth (CAGR) in Gross Profit (as defined in the Annual Report and Accounts) over the four-year period. The number of shares awarded that will vest at different performance levels is as follows: .................... Threshold: 10% p.a. Gross Profit CAGR................ Target: 20% p.a. Gross Profit CAGR................ Stretch: 30% p.a. Gross Profit CAGR................ In addition there will be a Profit after Tax (“PAT”) and share price underpin. The PAT underpin will operate such that a minimum of 10% p.a. growth must be achieved for vesting up to the Target level, with 20% p.a. PAT growth required for vesting between Target and Stretch levels. The Gross Profit and PAT growth levels are designed to represent organic growth and as such the Remuneration Committee retains the discretion to make adjustments to the targets and/or the performance measures to take account of any acquisitions or other material events. The absolute share price underpin will be determined on grant but will be no less than 130% of the mid-market price of the shares on the day the awards are granted. This underpin further mitigates against payment for failure.  Chief Executive Officer As the Company founder, the Chief Executive Officer, Mr. John Kearon, already holds almost 30% of the Company’s shares, and the Remuneration Committee believes that the award of further equity options to him would be inappropriate. It is therefore planning on putting in place an Annual Bonus for the Chief Executive Officer, recognising his strategic leadership of the Company to achieve these demanding growth targets, which would pay an annual cash bonus of 25% – 75% of basic salary if Gross Profit grows by 10% p.a. - 30% p.a. CAGR as described above, subject also to the profit underpin levels applying to the LTIP. -------------------- Fingers crossed re: formatting. Apols in advance if it goes awry! |
Posted at 25/1/2017 18:23 by longshanks I have a few favourite plays crazycoop although I am going to hold it in cash for the time being (my favourite asset class)I do follow stockopedia and rate their commentary.Graham Neary is a faithful follower of BJU but (as far as I know) has never bought in. The 3-year and 1-year comparison trends with NFC/YOU in the header is quite a good means of seeing current performance. Over 3 years BJU still has some way to catch up. It is though certainly outperforming the two larger companies since announcing a return to double-digit growth in December. Cannacord have given a tp of £7.20 which I feel is a little low and I can imagine some funds wanting to buy in at up to £8.The company is close to a £100m market cap. That may well result in added attention and with it better liquidity. |
Posted at 20/1/2017 07:41 by longshanks Really good, positive TU.37% increase in PTP, cash higher than last year and done so after returning almost all of last years cash balance in share buybacks and dividends.Their "sticky" customer tools for brand development are really taking hold so forward revenue visibility should become clearer.All-in-all a very positive set of details.The share price has motored ahead in anticipation of these details but we should now see further broker upgrades. My guess would be £7.50 - given gross profit was ahead 25% (15% in constant currency terms). |
Posted at 19/1/2017 17:35 by longshanks Thanks crazycoops.I thought it would be interesting to compare against NFC and YOU - so added this too as you may have noticed. NFC really has been an excellent investment with year-on-year growth since birth. YOU had a rocky few years - but it too has proven an excellent investment over the last 3 to 5 years. BJU is definitely behind the curve on both of these two larger peer companies, but it would seem it is definitely in "catch-up". The one big difference is that NFC and YOU have grown through acquisition and whilst both are strong cash generators they have financed much of that acquisition through debt. BJU has no debt and tends to return surplus cash back to shareholders. That difference in leverage could well account for the deviation in share price performance. I personally prefer the transparency of BJU's balance sheet though: it is clear at a glance whereas the balance sheets of the other two are something of a minefield. BJU has invested small amounts in new innovations - some disappear like "Digividuals" but the new investment in System1 Agency looks like it has real potential: strong on fluency to coin one of their phrases. If this new corporate branch works it will be transformational and the rate of return far higher than a more traditional acquisition would have proven. If it fails - BJU writes off £300k. That sounds like sensible, manageable risk to me. Interesting times. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
